preview

Does Hpv Vaccination Within Msm Significantly Prevent Anogenital Infection Occurrence And Recurrence Syndrome?

Best Essays

Clinical Question: Does HPV vaccination in MSM significantly prevent anogenital neoplasia occurrence and recurrence compared to not being vaccinated? Introduction Anogenital cancer (rectal, anal, anal canal, anorectum, penis and other genital) rates are on the rise with 27,660 estimated new male cases and 710 estimated male deaths in the United States last year alone.1 Currently, the Center for Disease Control (CDC) recommends vaccination in the men who have sex with men (MSM) population up to age 26 if they had not received it when they were younger.2 There are no current recommendations for this population who are greater than age 26 who have not previously received the vaccine. As age of an individual and number of lifetime sexual partners increases, the risk of developing anal cancer also increases. Men who have had >15 sexual partners during their lifetime show an increase in risk of developing anal cancer (OR=5.3; 95% CI, 2.4-12.0). Additionally, men who practice receptive anal intercourse is independently related to an increased risk of developing anal cancer (OR=6.8; 95% CI 1.4-33.8).3 These findings suggest that the MSM population, especially the aging MSM population, is a high-risk group that could benefit from vaccination protecting against the strains of Human Papiloma Virus (HPV) that are associated with cancer development. This growing need is addressed through extensive research of relevant literature answering the question “Does HPV vaccination in MSM

Get Access